GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Market Cap

CMPX (Compass Therapeutics) Market Cap : $403.79 Mil (As of Jul. 15, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Compass Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Compass Therapeutics's share price for the quarter that ended in Mar. 2025 was $1.9. Compass Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2025 was 138.28 Mil. Therefore, Compass Therapeutics's market cap for the quarter that ended in Mar. 2025 was $262.74 Mil.

Compass Therapeutics's quarterly market cap declined from Sep. 2024 ($253.16 Mil) to Dec. 2024 ($199.84 Mil) but then increased from Dec. 2024 ($199.84 Mil) to Mar. 2025 ($262.74 Mil).

Compass Therapeutics's annual market cap declined from Dec. 2022 ($635.30 Mil) to Dec. 2023 ($199.16 Mil) but then increased from Dec. 2023 ($199.16 Mil) to Dec. 2024 ($199.84 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Compass Therapeutics's Enterprise Value for Today is $267.11 Mil.


Compass Therapeutics Market Cap Historical Data

The historical data trend for Compass Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Therapeutics Market Cap Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial - 319.64 635.30 199.16 199.84

Compass Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 272.43 137.59 253.16 199.84 262.74

Competitive Comparison of Compass Therapeutics's Market Cap

For the Biotechnology subindustry, Compass Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Compass Therapeutics's Market Cap falls into.


;
;

Compass Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Compass Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=$1.45*137.820
=$199.84

Compass Therapeutics's Market Cap for the quarter that ended in Mar. 2025 is calculated as

Market Cap (Q: Mar. 2025 )=Share Price (Q: Mar. 2025 )*Shares Outstanding (EOP) (Q: Mar. 2025 )
=$1.9*138.282
=$262.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compass Therapeutics  (NAS:CMPX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Compass Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Compass Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Executives
Thomas J. Schuetz director, officer: Chief Executive Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard S Lindahl director NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
David M Wurzer director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Vered Bisker-leib officer: Chief Operating Officer C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Philip Ferneau director 10 ALLEN STREET, HANOVER NH 03755
Orbimed Capital Gp V Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled officer: Chief Scientific Officer COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016